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Abstract
Granzyme A, a serine protease expressed in the granules of cytotoxic T and Natural Killer
cells, is involved in the generation of pro-inflammatory cytokines by macrophages. Gran-
zyme A has been described to induce in macrophages in vitro the activation of pro-inflam-
matory pathways that impair intracellular mycobacterial replication. In the present study, we
explored the physiological relevance of Granzyme A in the control of pulmonaryMycobac-
terium tuberculosis infection in vivo. Our results show that, even though Granzyme A is
expressed by cytotoxic cells from mouse lungs during pulmonary infection, its deficiency in
knockout mice does not have an effect in the control ofM. tuberculosis infection. In addition
our findings indicate that absence of Granzyme A does not affect the protection conferred
by the live-attenuatedM. tuberculosis vaccine MTBVAC. Altogether, our findings are in
apparent contradiction with previously published in vitro results and suggest that Granzyme
A does not have a crucial role in vivo in the protective response to tuberculosis.
Introduction
Tuberculosis is one of the leading infectious diseases affecting mainly developing and underde-
veloped countries, and causing more than one million deaths per year. Thus, there is an urgent
need to develop new preventive, treatment and diagnostic strategies which allow to efficiently
reduce this widespread pandemia [1]. Comprehension of the mechanisms underlying the inter-
action between host immune system andMycobacterium tuberculosis will aid in the rational
design of such strategies to fight tuberculosis.
Granzymes (GZMs) are a family of serine-proteases whose expression has been classically
associated with cytotoxic cells, mainly CD8+ and NK cells. Granzymes, especially granzyme B,
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play an important role in cell cytotoxicity [2]. Upon recognition of target cells, effector cells
secrete granzymes via granule exocytosis, which reach the target cell citosol through membrane
pores conformed by perforin oligomers. The observation that not all GZMs have cytotoxic
capacity [3] and some of them like GZMA, GZMK and GZMM present pro-inflammatory
potential [4, 5], has opened a debate in the last years about the non-cytotoxic roles of this fam-
ily of proteases. GZMA is well recognized to be involved in inflammation, triggering the release
of cytokines, such as IL1β, in macrophages. Indeed, absence of GZMA provides a considerable
resistance to pro-inflammatory disorders like endotoxemia [5] and bacterial sepsis [6].
A previous work has analyzed the role of perforin and GZMB in vivo in the outcome of
tuberculosis infection, finding that these molecules do not have a major contribution to bacte-
rial clearance [7]. With regard to GZMA, several authors have described an increase of its pro-
tein levels in serum of patients with active tuberculosis [8, 9]. In addition, a recent study
reported that inflammation induced by GZMA could impair intracellular mycobacterial repli-
cation in macrophages in vitro [10]. However, there is no data in vivo about the role of GZMA
in the context of tuberculosis infection. In this work we analyzed the expression of GZMA in
lungs from tuberculosis-infected mice and we used a mouse GZMA knockout strain to study
the role of this molecule in protection against primary tuberculosis infection before and after
vaccination with the live-attenuatedM. tuberculosis vaccine candidate MTBVAC [11, 12].
Materials and Methods
Mycobacteria
Mycobacterial strains H37Rv [13] and MTBVAC [11] were grown at 37°C in Middlebrook
7H9 broth (BD Biosciences) supplemented with ADC (BD Biosciences) and 0.05% (v/v)
Tween-80, or on solid Middlebrook 7H11 (BD Biosciences) supplemented with ADC. Bacterial
suspensions for vaccination or infection were prepared in PBS from previously quantified
mycobacterial glycerol stocks.
Ethics Statement
Experimental work was conducted in agreement with European (Directive 2010/63/EU) and
National (Real Decreto 53/2013) directives for protection of laboratory animals. All experi-
mental procedures with animals described in this work were previously revised and approved
by the “Comisión Ética Asesora de Experimentación Animal” (CEA) of the University of Zara-
goza (Approved protocol number PI17/14).
Mice
C57BL/6 wild type (Janvier Biolabs) or GZMA-knockout (provided by Markus Simon, [14])
mice were bred under specific pathogen free (SPF) conditions. GzmA-/- mice were originally
generated as described by Ebnet et al. [14], and were backcrossed into the C57BL/6 background
more than 10 times. Groups of eight- to twelve-week old male and female mice were intrana-
sally challenged with low dose (100–150 CFU) ofM. tuberculosisH37Rv in 40 μl of PBS. Four
weeks later, mice were sacrificed and lungs were harvested for the subsequent analysis. To
determine bacterial load in lungs, organs were homogenized and plated on solid agar medium.
To characterize lung cell populations, lungs were incubated with DNAase I (Applichem) and
Collagenase D (Roche) in order to obtain a cellular suspension. In vaccination experiments,
mice were immunized subcutaneously with 106 CFU of MTBVAC vaccine in 100 μl of PBS
eight weeks prior to challenge. For survival experiments, mice were challenged intranasally
with a high dose (1000 CFU) of H37Rv. Weight loss (assessed twice a week) and physical aspect
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(assessed daily) were monitored to evaluate disease progression and mice were humanely
euthanized according to accepted pre-established endpoint criteria. These criteria were loss of
20% of body weight or physical changes associated with pain as appearance of piloerection or
arched back. Animals were euthanized in all cases by CO2 inhalation. No animals died before
meeting the established humane endpoint criteria.
Flow cytometry
For cellular surface staining, cells were labelled with antiCD4-FITC, antiCD8-PE, anti-
NK1.1-PE, antiLy6G-Pacific Blue, antiCD11b-PE (BD Biosciences) or antiCD11c-FITC (Milte-
nyi Biotec) diluted in RPMI 1640 culture medium with 10% foetal calf serum (FCS). To
determine GZMA-positive populations, cells were fixed and permeabilized with the Cytofix/
Cytoperm Fixation/Permeabilization Kit (BD Biosciences) following manufacturer instruc-
tions. Cells were stained with antiGZMA antibody diluted 1:100 (provided by Markus Simon
[15]), followed by incubation with a secondary antibody APC-conjugated anti-rabbit IgG
(eBiosciences). To analyze IFNγ-producing cells, these were incubated overnight with Purified-
Protein Derivative (PPD) 10μg/ml (Statens Serum Institute, SSI). Golgi inhibitor GolgiPlug
(BD Biosciences) was added to cells during the last six hours of incubation. Cells were then
fixed and permeabilized with the Cytofix/Cytoperm Fixation/Permeabilization Kit and stained
with anti-IFNγ-APC (BD Biosciences).
Statistical Analysis
GraphPrism software was used for statistical analysis. For experiments with two experimental
groups, unpaired t-student test was used. When three or more groups were compared, One-
Way ANOVA analysis with Bonferroni post-test was performed. Differences were considered
significant at p<0.05.
Results and Discussion
GZMA is expressed in lungs from TB-infected mice.
To evaluate GZMA expression in lung cells, we first assessed the specificity of antibody used
for GZMA detection by intracellular staining and flow cytometry. GZMA-positive cells were
detected only in lung cells from wild-type (WT) but not from GZMA knockout (GZMA-/-)
mice (Fig 1A). Our data revealed a significant 5-fold increase in the absolute number of
GZMA-expressing cells inM. tuberculosisH37Rv-infected lungs compared to non-infected
mice (Fig 1B). In terms of percentage, GZMA was expressed in approximately 9% of total cells
in uninfected mice reaching more than 13% at four weeks post-infection. Then, we character-
ized by flow cytometry the GZMA-expressing cellular subsets in the GZMA-positive gated
region (Fig 1C). Most of the GZMA-positive cells (> 95%) in non-infected mice were positive
for the NK1.1 surface marker with a small proportion of CD8+ and CD4+ T cells, indicating
that in the absence of infection GZMA expression in lungs is mainly restricted to NK cells.
Conversely, four weeks post-infection, percentage of NK1.1-positive GZMA-expressing cells
decreased to 80%, due to the substantial increase observed in the percentage of GZMA-positive
CD8+ and CD4+ T cells, (15% and 5%, respectively). In concurrence with these observations,
both frequency and absolute number of CD4+ and CD8+ GZMA-expressing cells dramatically
increased in lungs upon infection (Fig 1D). Tuberculosis infection also led to an increase in the
number of GZMA-expressing NK cells. In addition, we also analysed the presence of GZMA in
neutrophils as expression of GZMA in human neutrophils has been reported [16]. However,
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Fig 1. Granzyme A expression is increased in lungs afterM. tuberculosis infection. A, lung cells fromWT or GZMA-/- mice were intracellularly stained
with anti-GZMA. A representative dot-plot showing GZMA staining is shown. GZMA-positive cells are contained in the red-circled region.B, C, D, Groups of
five C57BL/6 wild-type mice were inoculated intranasally with a low-dose H37Rv challenge. Four weeks later, mice were sacrificed and GZMA expression
analyzed in lung cellular populations. B, total GZMA-expressing cells.C, GZMA-expressing cell populations. Graph shows the relative proportions in
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we did not find GZMA-expression in mouse lung neutrophils (S1 Fig) confirming previous
results in the mouse model [17].
Altogether, these data showed that an important number of GZMA-positive cells are infil-
trated inM. tuberculosis-infected lungs, suggesting that this molecule could have a role in the
outcome of tuberculosis infection.
GZMA is not involved in protection against tuberculosis
To elucidate the possible contribution of GZMA in the control of tuberculosis infection, WT
and GZMA-/- mice were intranasally challenged with low-dose H37Rv. Four weeks after infec-
tion no difference in lung bacterial burden was found in WT and GZMA-/- mice (Fig 2A),
percentage of the GZMA-positive cell populations. Right panels show representative CD4, CD8 and NK1.1 staining dot-plots and histogram gated from a
GZMA-positive region. D, graphs show frequency (upper panels) and absolute number (lower panels) of CD4, CD8 and NK cells positive for GZMA staining,
comparing non-infected and infected mice. A representative of two independent experiments is shown in the Figure. Data in the graphs are represented as
mean ± SEM. Unpaired t-student analysis was performed to calculate statistical significance. * p<0.05; ** p<0.01; *** p<0.001.
doi:10.1371/journal.pone.0153028.g001
Fig 2. GZMA-/- mice are not more susceptible toM. tuberculosis infection.Groups of nine C57BL/6 wild-type or GZMA-/- mice were inoculated
intranasally with a low-dose (A) or high-dose (B) H37Rv challenge.A, four weeks later bacterial burden in lungs was determined. A representative of two
independent experiments is shown in the graph. B, animal survival (left panel) was determined according to pre-established endpoint criteria approved by an
ethical committee. Data from one experiment are represented in a Kaplan-Meier survival curve. Lung bacterial burden in survivor animals was analyzed (right
panel).
doi:10.1371/journal.pone.0153028.g002
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suggesting no role of GZMA in controlling short-term infection. To assess whether GZMA
could participate in controlling infection at long term, we evaluated survival after intranasal
high-dose H37Rv challenge. As seen in Fig 2B, the survival rate of WT and GZMA-/- mice was
similar at 30 weeks post infection, concluding that GZMA is not involved in long-term protec-
tion in our model. Consequently, no differences were found between both genetic backgrounds
when analyzed lung bacterial burden in survivor animals (Fig 2A, right panel). Data shown in
S2 Fig confirm no variation in lung cell populations (CD8, CD4, NK cells, neutrophils and
dendritic cells) in GZMA-/- mice as compared to WT before and after tuberculosis infection.
Our in vivo data contrast with a previous work showing that in vitro GZMA inhibits mycobac-
terial replication in macrophages [10]. This discordance could be explained by the difference in
in vitro and in vivo conditions tested in both studies. In addition, our data do not necessarily
exclude a role for GZMA in mycobacterial clearance, but that in its absence, other pathways
could compensate its function.
Although we observed that GZMA is not involved in the control of tuberculosis infection,
we sought to investigate whether it contributes to protection conferred by vaccination. To test
this hypothesis, we used the live vaccine candidate MTBVAC [11, 12] for evaluation of protec-
tive efficacy against H37Rv challenge in WT and GZMA-/- mice. Our data revealed that vacci-
nation reduced bacterial burden in both mouse strains to a similar extent, suggesting that
GZMA is not relevant for vaccine-induced protective efficacy (Fig 3A). Interestingly, vaccina-
tion with MTBVAC induced similar PPD-specific IFNγ-producing CD4+ T-cell response
regardless of GZMA presence; likely indicating that GZMA does not contribute to generation
of the vaccine-induced protective response (Fig 3B). Translating these data to clinical applica-
tion of MTBVAC could suggest that vaccine-conferred protection would not be affected by
potential loss-of-function GZMA gene polymorphisms.
Fig 3. GZMA-/- mice are not less protected by MTBVAC vaccination.Groups of nine C57BL/6 WT or GZMA-/- mice were vaccinated subcutaneously with
106 CFU of MTBVAC (WT VAC or GZMA-/- VAC), or non-vaccinated. A, at two months post-vaccination, mice were inoculated intranasally with a low-dose
challenge of H37Rv, and four weeks later lung bacterial burden was determined. Data from one experiment are represented in the graph. One-way ANOVA
test with Bonferroni post analysis was performed to calculate statistical significance. * p<0.05; ** p<0.01; *** p<0.001.B, cells were stimulated with PPD as
described in materials and methods section, and CD4+IFNγ+ cells frequency in lungs was determined by flow cytometry. Data from one experiment are
represented in the graph as mean± SEM.
doi:10.1371/journal.pone.0153028.g003
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Altogether, our data are in concordance with different works that show serum GZMA
increase in patients with active tuberculosis [8, 9]. However, our results do not reveal any con-
tribution of GZMA in the control of tuberculosis infection or in protective efficacy conferred
by vaccination with MTBVAC. Thus, we suggest that the increase in GZMA expression
observed in tuberculosis patients could be a consequence of immune system activation during
the progression of disease rather than an effector mechanism to fight infection.
In some experimental models lack of GZMA has been shown to reduce susceptibility to
inflammatory disorders like endotoxemia [4, 5] or bacterial sepsis [6] suggesting that GZMA-
targeting inhibitors may be a potential attractive alternative to treat diverse inflammatory dis-
orders. Our data suggest that potential use of GZMA-inhibitors would not increase risk of
tuberculosis reactivation in latently-infected individuals, as observed in certain tuberculosis
patients receiving anti-TNFα therapy [18] and as result have required tuberculosis prophylaxis
treatment [19].
Supporting Information
S1 Fig. Granzyme A is not expressed by lung neutrophils. Groups of WT mice were infected
intranasally with a low-dose challenge of H37Rv, or non-infected. Neutrophils were defined as
CD11b+Ly6G+ cells, and analyzed in Granzyme A- negative- or positive- gated regions. A rep-
resentative dot-plot of obtained from a non-infected and a tuberculosis-infected mouse is
shown in the Figure.
(TIF)
S2 Fig. Lung cellular populations in GZMA-/- mice afterM. tuberculosis infection. Groups
of WT or GZMA-/- mice were infected intranasally with a low-dose challenge of H37Rv. Four
weeks later, lung cellular suspensions were prepared and CD4, CD8, NK cell, neutrophil
(Ly6G+CD11b-) and Dendritic cell (CD11bhighCD11chigh) populations analyzed by flow
cytometry. Data in the graphs compare infected and non-infected mice and are represented as
mean± SEM.
(TIF)
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